[go: up one dir, main page]

WO2015063099A1 - Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey - Google Patents

Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey Download PDF

Info

Publication number
WO2015063099A1
WO2015063099A1 PCT/EP2014/073139 EP2014073139W WO2015063099A1 WO 2015063099 A1 WO2015063099 A1 WO 2015063099A1 EP 2014073139 W EP2014073139 W EP 2014073139W WO 2015063099 A1 WO2015063099 A1 WO 2015063099A1
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
msh
phe
hailey
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/073139
Other languages
English (en)
Inventor
Philippe Wolgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLINUVEL AG
Original Assignee
CLINUVEL AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLINUVEL AG filed Critical CLINUVEL AG
Publication of WO2015063099A1 publication Critical patent/WO2015063099A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to alpha-MSH analogues, particularly afamelanotide, for use in a medical indication and to a medical treatment using alpha-MSH analogues, particularly afamelanotide, and to alpha-MSH analogues, particularly afamelanotide, for the manufacture of a medicament.
  • Hailey-Hailey disease is associated with rashes and blisters on the skin and is due to a genetic defect.
  • Available treatments include topical steroids, methotrexate, and thalidomine.
  • Related infections may be treated with antibiotics or antifungals.
  • the present invention provides for a simple, effective and safe treatment of Hailey-Hailey disease using a preferred dosing regimen. Accordingly, in one aspect, the present invention is directed to alpha-MSH analogue for use in treating a human subject suffering from Hailey-Hailey disease, wherein the interval between subsequent administrations of the alpha- MSH analogue is at least 5 weeks and at most 8 weeks. Preferably, the interval between subsequent administrations of the alpha-MSH analogue is at least 6 weeks.
  • the alpha-MSH analogue is administered systemically.
  • the alpha-MSH analogue is administered subcutaneously.
  • the alpha-MSH analogue is present in the blood plasma of the subject at a level of between at least O.Olng/ml to at most lOng/ml for at least 2 days.
  • the alpha-MSH analogue is administered at least 3 times to the subject.
  • the alpha-MSH analogue is administered at most 24 times to the subject.
  • the alpha-MSH analogue is a derivative of alpha-MSH which exhibits agonist activity for the melanocortin-l-receptor (MC1R), the receptor to which alpha-MSH binds to initiate the production of melanin within a melanocyte.
  • M1R melanocortin-l-receptor
  • the alpha-MSH analogue is afamelanotide and the interval between subsequent administrations of the afamelanotide is at least 5 weeks and at most 8 weeks.
  • the alpha-MSH analogue is administered to the subject in the form of an implant comprising 16mg afamelanotide.
  • the invention is directed to the use of an alpha-MSH analogue for the manufacture of a medicament for the treatment of Hailey-Hailey disease, wherein the interval between subsequent administrations of the alpha-MSH analogue is at least 5 weeks and at most 8 weeks.
  • invention is directed to the treatment of a human subject suffering from Hailey-Hailey disease, wherein the interval between subsequent administrations of the alpha- MSH analogue is at least 5 weeks and at most 8 weeks.
  • lesion clearance can be improved while treatment side-effects such as tanning, scarring and/or coloring may be limited or avoided.
  • the present invention is directed to alpha-MSH analogues, particularly afamelanotide, for use in treatment of Hailey-Hailey disease. Further, the invention is directed to a medical treatment of Hailey-Hailey disease using alpha-MSH analogues, particularly afamelanotide. Further the invention is directed to use of alpha-MSH analogues, particularly afamelanotide, for the manufacture of a medicament for the treatment of Hailey-Hailey disease. Hailey-Hailey disease is rare disorder associated with skin rashes and blisters. The cause of the disorder seems related to a chromosomal defect. Treatment options are limited and not leading to optimal results or causing concerns for side-effects.
  • the alpha-MSH analogue, particularly afamelanotide is administered at least 3 times to a subject suffering from Hailey-Hailey disease, more preferably at least 6 times, most preferably at least 10 times and preferably at most 24 times and particularly preferred the alpha-MSH analogue, particularly afamelanotide, is administered 12 times.
  • the interval between subsequent administrations is at least 3 weeks, more preferably more than 4 weeks, most preferably more than 31 days and in particular preferred at least 5 weeks.
  • the interval between subsequent administrations is at most 8 weeks, more preferably at most 7 weeks, most preferably at most 6 weeks.
  • a particularly preferred range for the interval between subsequent administrations is between from 5 to 6 weeks.
  • the interval between subsequent administrations is at least 3 weeks, more preferably more than 4 weeks, most preferably more than 31 days and in particular preferred at least 5 weeks.
  • the interval between subsequent administrations is at most 8 weeks, more preferably at most 7 weeks, most preferably at most 6 weeks.
  • administrations is preferably at least 5 weeks, more preferably at least 6 weeks and preferably at most 10 weeks, more preferably at most 9 weeks and most preferably at most 8 weeks, with a preferred range for the interval being 5 to 8 weeks and a particularly preferred range being 6 to 8 weeks. It will be understood that for the purpose of the invention, the intervals are separate and subsequent and do not overlap.
  • the subject has the alpha-MSH analogue (preferably afamelanotide) blood plasma level -resulting from each administration- of at least O.Olng/ml, more preferably at least O.lng/ml, most preferably at least lng/ml and preferably at most 20ng/ml, more preferably at most 15ng/ml, most preferably at most lOng/ml and preferably for at least 1 day, more preferably at least 2 days, more preferably at least 5 days and preferably at most 30 days, more preferably at most 20 days, most preferably at most 15 days and particularly preferred for up to 10 days, for instance for 7 days or for 10 days.
  • O.Olng/ml more preferably at least O.lng/ml
  • most preferably at least lng/ml and preferably at most 20ng/ml more preferably at most 15ng/ml
  • most 15ng/ml most 15ng/ml
  • lOng/ml preferably for at least 1 day
  • the alpha-MSH analogue preferably afamelanotide
  • blood plasma levels are achieved after each administration.
  • the alpha-MSH analogue preferably afamelanotide
  • the alpha-MSH analogue is administered in an amount that results in the blood plasma levels indicated.
  • the human is subjected to the blood plasma levels indicated.
  • the alpha-MSH analogue, particularly afamelanotide is preferably systemically administered.
  • the alpha-MSH analogue, particularly afamelanotide is administered subcutaneously.
  • alpha-MSH analogues are directed to alpha-MSH analogues.
  • alpha- MSH analogue as used herein is defined as a derivative of alpha-MSH which exhibits agonist activity for the melanocortin-l-receptor (MC1 ), the receptor to which alpha-MSH binds to initiate the production of melanin within a melanocyte.
  • MC1 melanocortin-l-receptor
  • alpha-MSH analogues include derivatives in which (i) one or more amino acid residues are deleted from the native alpha- MSH molecule at the N-terminal end, the C-terminal end, or both; and/or (ii) one or more amino acid residues of the native alpha-MSH molecule are replaced by another natural, non- natural or synthetic amino acid residue; and/or (iii) an intra-molecular interaction forms as a cyclic derivative.
  • Several derivatives of alpha-MSH have been synthesized. In one aspect of the present invention, the alpha-MSH analogues described in US Patents Nos. 4,457,864,
  • alpha-MSH analogues 4,485,039, 4,866,038, 4,918,055, 5,049,547, 5,674,839 and 5,714,576 and Australian Patents Nos. 597630 and 618733, which are herein incorporated by reference for their teachings with respect to alpha-MSH analogues and their synthesis thereof, can be used herein.
  • the alpha- MSH analogue may be used as such or in the form of a pharmaceutically acceptable salt thereof.
  • the alpha-MSH analogue is a non-radiation emitting analogue, i.e. the compound is not radioactive that can be damaging to the body.
  • the alpha-MSH analogue emits low and preferably no radiation including alpha, beta and/or gamma radiation at the level or lower than average background radiation levels.
  • the alpha-MSH analogue is selected from the group consisting of:
  • M is Met, Nle or Lys
  • R x is absent, n-pentadecanoyl, Ac, 4-phenylbutyryl, Ac-Gly-, Ac-Met-Glu, Ac-Nle-Glu-, or Ac-Tyr-Glu-;
  • W is -His- or-D-His-;
  • X is -Phe-, -D-Phe-, -Tyr-, -D-Tyr-, or -(pN0 2 )D-Phe 7 -;
  • Y is -Arg- or -D-Arg-;
  • Z is -Trp- or -D-Trp-;
  • R 2 is -NH 2 ; -Gly-NH 2 ; or-Gly-Lys-NH 2 , as disclosed in Australian Patent No. 597630.
  • the alpha-MSH analogue may be a linear analogue as disclosed in US
  • alpha-MSH analogue may also be a cyclic analogue as disclosed in US Patent No. 5,674,839, selected from the group consisting of:
  • the alpha-MSH analogue is preferably selected from the group consisting of: [D-Phe 7 ]- -MSH, Nle 4 , D-Phe 7 ]-a-MSH, D-Ser 1 , D-Phe 7 ]-a-MSH ;
  • alpha-MSH analogues thereof are selected from the group consisting of:
  • the alpha-MSH analogue is a cyclic peptide of formula (I):
  • Z is H or an N-terminal group wherein the N-terminal group is preferably a Q to C 17 acyl group, wherein the d to C 17 comprises a linear or branched alkyl, cycloalkyl, alkylcycloalkyl, aryl or alkylaryl, a linear or branched Q to C17 alkyl, aryl, heteroaryl, alkene, alkenyl, or aralkyi chain or an N-acylated linear or branched C x to C 1 alkyl, aryl, heteroaryl, alkene, alkenyl, or aralkyi chain and more preferably is a Q to C 7 acyl group;
  • Xaa 1 is optionally present, and if present is from one to three L- or D-isomer amino acid residues, and preferably an amino with a side chain including a linear or branched alkyl, cycloalkyi, cycloheteroalkyl, aryl
  • Xaa 3 is L- or D-Pro, optionally substituted with hydroxyl, halogen, sulfonamide, alkyl,— O-alkyl, aryl, alkyl-aryl, alkyl-O-aryl, alkyl-O-alkyl-aryl, or— O-aryl, or Xaa 3 is an L- or D-isomer of an amino acid with a side chain including at least one primary amine, secondary amine, alkyl, cycloalkyi, cycloheteroalkyl, aryl, heteroaryl, ether, sulfide, or carboxyl and preferably is an L- or D-isomer of His;
  • Xaa 4 is an L- or D-isomer amino acid with a side chain including phenyl, naphthyl or pyridyl, optionally wherein the ring is substituted with one or more substituents independently selected from halo, (Cx-CjoJalkyl-halo, (Ci-Cio)alkyl, (Q-C t ojalkoxy, (QrCjolalkylthio, aryl, aryloxy, nitro, nitrile, sulfonamide, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, and alkoxy-carbonyl, and is preferably D-Phe, optionally substituted with one or more substituents independently selected from halo, (Ci-Cio)alkyl-halo, (Ci-C 10 )alkyl, (Ci-Cio)alkoxy, (Ci-Ci 0 )alkylthio
  • Xaa 5 is L- or D-Pro or an L- or D-isomer amino acid with a side chain including at least one primary amine, secondary amine, guanidine, urea, alkyl, cycloalkyi, cycloheteroalkyl, aryl, heteroaryl, or ether and preferably is an L- or D-isomer of Arg, Lys, Orn, Dab or Dap;
  • Xaa 7 is optionally present, and if present is from one to three L- or D-isomer amino acid residues, and is preferably an amino acid with a side chain including at least one aryl or heteroaryl, optionally substituted with one or more ring substituents, and when one or more substituents are present, are the same or different and independently hydroxyl, halogen, sulfonamide, alkyl, -O-alkyl, aryl, or -O-aryl, and more preferably is an L- or D-isomer of Trp, Nal l or al 2; and
  • Y is a C-terminal group and in another aspect preferably a hydroxyl, an amide, or an amide substituted with one or two linear or branched Q. to C 17 alkyl, cycloalkyi, aryl, alkyl cycloalkyi, aralkyl, heteroaryl, alkene, alkenyl, or aralkyl chains.
  • Preferred cyclic alpha-MSH analogues are Ac-Nle-cyclo(Glu-His-D-Phe-Arg-Dab)-Trp-NH 2 and Ac-Nle-cyclo(Glu-His-D-Phe-Arg-Dap)-Trp-NH 2 .
  • amino acids are defined in US2013/0296256 pages 5 and 6 which are incorporated herein by reference.
  • the most preferred alpha-MSH analogue is [Nle 4 , D-Phe 7 ]- alpha-MSH.
  • Afamelanotide as used in the present invention is the generic name for [Nle 4 , D- Phe 7 ]-alpha MSH, a synthetic analogue of natural alpha MSH. This preferred compound is sometimes referred to as NDP-MSH. It is also generically known as afamelanotide, which is available as an implant formulation under the trademark SCENESSE ® .
  • Alpha-MSH analogues according to the present invention may also be used in the form of a pharmaceutically acceptable salt thereof.
  • Preferred examples of such salts are acetate, trifluoroacetate, sulphate, and chloride salts.
  • the acetate salt is generally most preferred.
  • the alpha-MSH analogue is administered in the form of composition, more preferably in the form of an implant.
  • the alpha-MSH analogue, particularly afamelanotide, implants are described in US2008/0305152 (Kleinig et al.) which is incorporated herein by reference.
  • the composition comprises at least 5mg the alpha-MSH analogue (preferably afamelanotide), more preferably at least lOmg and preferably at most 30mg, more preferably at most 25mg.
  • Particularly preferred amounts are 20mg or 16mg the alpha-MSH analogue (preferably afamelanotide) with 16mg afamelanotide being most preferred amount.
  • the % by weight of the alpha-MSH analogue (preferably afamelanotide) that is encapsulated or incorporated in the biodegradable polymer will vary depending upon the selection of the biodegradable polymer, the encapsulation or incorporation technique, and the amount of the alpha-MSH analogue (preferably afamelanotide) to be delivered to the subject.
  • the amount of the alpha-MSH analogue (preferably afamelanotide) encapsulated in the implant can be up to 50% by weight of the implant. In other aspects, the amount of the alpha-MSH analogue (preferably afamelanotide) encapsulated in the implant is preferably from 5% to 60%, more preferably from 10% to 50%, most preferably from 15% to 40%, and in particularly preferred from 15% to 30% by weight of the implant.
  • the composition comprises a controlled release formulation.
  • the implant (or rod) comprises a biodegradable polymer, wherein the alpha-MSH analogue (preferably afamelanotide) is imbedded within the implant.
  • the alpha-MSH analogue particularly afamelanotide, is encapsulated in an implant composed of poly(lactide-co-glycolide), poly(lactide), poly(glycolide), or a mixture thereof.
  • Lactide/glycolide polymers for drug-delivery formulations are typically made by melt polymerization through the ring opening of lactide and glycolide monomers. Some polymers are available with or without carboxylic acid end groups.
  • the end group of the poly(lactide-co-glycolide), poly(lactide), or poly(glycolide) is not a carboxylic acid, for example, an ester, then the resultant polymer is referred to herein as blocked or capped.
  • the unblocked polymer conversely, has a terminal carboxylic group.
  • linear lactide/glycolide polymers are used; however star polymers can be used as well.
  • high molecular weight polymers can be used for medical devices, for example, to meet strength requirements.
  • the lactide portion of the polymer has an asymmetric carbon. Commercially racemic DL-, L-, and D-polymers are available.
  • the L- polymers are more crystalline and resorb slower than DL- polymers.
  • copolymers comprising glycolide and DL-lactide or L- lactide
  • copolymers of L-lactide and DL-lactide are available.
  • homopolymers of lactide or glycolide are available.
  • the biodegradable polymer is poly(lactide- co-glycolide), poly(lactide), or poly(glycolide)
  • the amount of lactide and glycolide in the polymer can vary.
  • the biodegradable polymer contains 0 to 100 mole %, 40 to 100 mole %, 50 to 100 mole %, 60 to 100 mole %, 70 to 100 mole %, or 80 to 100 mole % lactide and from 0 to 100 mole %, 0 to 60 mole %, 10 to 40 mole %, 20 to 40 mole %, or 30 to 40 mole % glycolide, wherein the amount of lactide and glycolide is 100 mole %.
  • the biodegradable polymer can be poly(lactide), 85:15 poly(lactide-co-glycolide), 75:25 poly(lactide-co-glycolide), or 65:35 polylactide-co-glycolide) where the ratios are mole ratios.
  • the biodegradable polymer when the biodegradable polymer is poly(lactide-co-glycolide), poly(lactide), or poly(glycolide), the polymer has an intrinsic viscosity of from 0.15 to 1.5 dL/g, 0.25 to 1.5 dL/g, 0.25 to 1.0 dL/g, 0.25 to 0.8 dL/g, 0.25 to 0.6 dL/g, or 0.25 to 0.4 dL/g as measured in chloroform at a concentration of 0.5 g/dL at 30°C.
  • the pharmaceutically-acceptable component can include, but is not limited to, a fatty acid, a sugar, a salt, a water-soluble polymer such as polyethylene glycol, a protein, polysacharride, or carboxmethyl cellulose, a surfactant, a plasticizer, a high- or low- molecular- weight porosigen such as polymer or a salt or sugar, or a hydrophobic low- molecular-weight compound such as cholesterol or a wax.
  • the implant comprises [Nle 4 , D- Phe 7 ]- alpha-MSH in the amount from 15% to 45% by weight of the implant, wherein the implant comprises poly(lactide) or poly(lactide-co-glycolide) such as, for example, 85:15 poly(lactide-co-glycolide).
  • Preferred implants are described in US2008/0305152. A preferred implant is available under the name of Scenesse ® in Italian and Swiss markets.
  • Afamelanotide is subcutaneously administered to subjects suffering from Hailey Hailey disease in the form of 16mg implants and with subsequent administration intervals of from 6 to 8 weeks. Afamelanotide was systemically released from each implant for at least 2 days, with plasma levels of between O.OOOlng/ml and lOng/ml during this period.
  • preferred embodiments of the invention include:
  • Embodiment 1 Afamelanotide for use in treating a human subject suffering from Haiiey-Hailey disease, wherein afamelanotide is administered at least 3 times to the subject, wherein after each administration afamelanotide is present in the blood plasma of the subject at a level of between at least O.Olng/ml to at most lOng/ml for at least 2 days, and wherein the interval between subsequent administrations of afamelanotide is between at least 3 weeks and at most 6 weeks.
  • Embodiment 2 Compound for use according to embodiment 1, wherein afamelanotide is administered systemically.
  • Embodiment 3 Compound for use according to embodiments 1-2, wherein afamelanotide is subcutaneously administered.
  • Embodiment 4 Compound for use according to embodiments 1-3, wherein afamelanotide is administered to the subject in the form of an implant comprising 16mg afamelanotide.
  • Embodiment 5 Compound for use according to embodiments 1-4, wherein afamelanotide is administered at least 10 times to the subject with an interval between subsequent administrations of between at least 5 weeks and at most 6 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des analogues de l'alpha-MSH destinés à être utilisés dans le traitement de la maladie de Hailey-Hailey.
PCT/EP2014/073139 2013-10-28 2014-10-28 Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey Ceased WO2015063099A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190556 2013-10-28
EP13190556.4 2013-10-28

Publications (1)

Publication Number Publication Date
WO2015063099A1 true WO2015063099A1 (fr) 2015-05-07

Family

ID=49518690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/073139 Ceased WO2015063099A1 (fr) 2013-10-28 2014-10-28 Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey

Country Status (1)

Country Link
WO (1) WO2015063099A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546035A (zh) * 2020-04-23 2021-10-26 克林维尔制药有限公司 具有圆柱形形状的药物植入物装置及多部分套件

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4866038A (en) 1986-02-03 1989-09-12 University Patents, Inc. Method of stimulating integumental melanocytes by topical application of analogs of alpha-msh
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
AU618733B2 (en) 1987-05-22 1992-01-09 University Patents Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
WO2008025094A1 (fr) * 2006-08-31 2008-03-06 Clinuvel Pharmaceuticals Limited Méthode de traitement de photodermatoses
US20080305152A1 (en) 2004-08-04 2008-12-11 Clinuvel Pharmaceuticals Limited Methods of Inducing Melanogenesis in a Subject
US20130203670A1 (en) * 2008-03-27 2013-08-08 Clinuvel Pharmaceuticals Limited Therapy For Vitiligo
US20130296256A1 (en) 2009-11-23 2013-11-07 Palatin Technologies, Inc. Melanocortin-1 Receptor-Specific Cyclic Peptides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4866038A (en) 1986-02-03 1989-09-12 University Patents, Inc. Method of stimulating integumental melanocytes by topical application of analogs of alpha-msh
US4918055A (en) 1986-02-03 1990-04-17 Hruby Victor J Method of stimulating melanocytes by topical application of analogs of alpha-MSH, and compositions for use in same
AU597630B2 (en) 1986-02-03 1990-06-07 University Patents Inc. Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
AU618733B2 (en) 1987-05-22 1992-01-09 University Patents Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5714576A (en) 1987-05-22 1998-02-03 Competitive Technologies, Inc. Linear analogs of alpha-msh fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US20080305152A1 (en) 2004-08-04 2008-12-11 Clinuvel Pharmaceuticals Limited Methods of Inducing Melanogenesis in a Subject
WO2008025094A1 (fr) * 2006-08-31 2008-03-06 Clinuvel Pharmaceuticals Limited Méthode de traitement de photodermatoses
US20130203670A1 (en) * 2008-03-27 2013-08-08 Clinuvel Pharmaceuticals Limited Therapy For Vitiligo
US20130296256A1 (en) 2009-11-23 2013-11-07 Palatin Technologies, Inc. Melanocortin-1 Receptor-Specific Cyclic Peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. BIOLCATI ET AL: "Efficacy of the melanocortin analogue Nle4-D-Phe7-[alpha]-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease", CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1 October 2013 (2013-10-01), pages n/a - n/a, XP055092137, ISSN: 0307-6938, DOI: 10.1111/ced.12203 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113546035A (zh) * 2020-04-23 2021-10-26 克林维尔制药有限公司 具有圆柱形形状的药物植入物装置及多部分套件

Similar Documents

Publication Publication Date Title
JP5242415B2 (ja) 高い安定性を持つ薬理組成物
CA2960334A1 (fr) Formulations pharmaceutiques pour l'administration par voie orale de medicaments de type peptide ou proteine
ES2656131T3 (es) Terapia para el vitíligo
US11993640B2 (en) Treating inflammatory lung disease
EA033590B1 (ru) Препараты с контролируемым высвобождением
TWI715520B (zh) 用於持續釋放蘭瑞肽之醫藥組成物
AU2017443632B2 (en) Pharmaceutical compositions having a selected release duration
JP2017513856A (ja) 毛成長抑制のためのオステオポンチン誘導体を含む組成物
AU2012270024B2 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
EP3573645B1 (fr) Analogues d'alpha-msh utilisés dans le traitement du xeroderma pigmentosum
EP3212219A1 (fr) Nouvelle indication pour des analogues d'alpha-msh
WO2015063099A1 (fr) Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey
KR101838759B1 (ko) 점안제
WO2015063102A1 (fr) Alpha-msh pour une utilisation dans le traitement de la maladie de hailey-hailey
CN113412116A (zh) 用于心脏保护的经修饰的轴突生长诱向因子-1肽和组合物
EP2705835A1 (fr) Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AU2014332346B2 (en) Novel peptide compositions
WO2015067503A1 (fr) Analogues de l'alpha-msh destinés à être utilisés dans le traitement du psoriasis
US20170360896A1 (en) Inflammatory disease
WO2021156857A1 (fr) Compositions comprenant de l'amélogénine et leurs utilisations
RU2025100211A (ru) Способы лечения ожирения агонистом mc4r
JP2006096751A (ja) インターロイキン−１１徐放性医薬組成物
WO2019078349A1 (fr) Matériau anti-adhérence
JPH06179628A (ja) 創傷治癒促進剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14799973

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14799973

Country of ref document: EP

Kind code of ref document: A1